Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

780.28
-5.2300-0.67%
Post-market: 780.300.0200+0.00%19:24 EST
Volume:586.82K
Turnover:457.39M
Market Cap:82.49B
PE:18.76
High:790.00
Open:783.17
Low:775.50
Close:785.51
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:0.72
T/O Rate:0.57%
Dividend:3.52
Dividend Rate:0.45%
EPS(TTM):41.59
EPS(LYR):41.48
ROE:14.87%
ROA:5.91%
PB:2.64
PE(LYR):18.81

Loading ...

Regeneron Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
Yesterday

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $975 From $865, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Regeneron price target raised to $975 from $865 at Guggenheim

TIPRANKS
·
Yesterday

Anavex Life Sciences ernennt Wolfgang Liedtke zum Global Head of Neurology

Reuters
·
Yesterday

Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks

TIPRANKS
·
Feb 05

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Feb 05

Regeneron Pharmaceuticals Inc. Publishes Transcript of Q4 2025 Earnings Conference Call

Reuters
·
Feb 05

Regeneron Pharmaceuticals veröffentlicht Transkript zur Q4 2025 Earnings Conference Call

Reuters
·
Feb 05

Regeneron meldet für das Gesamtjahr 2025 einen Anstieg des Anteils am Kollaborationsgewinn aus Dupixent- und Kevzara-Verkäufen auf 5,24 Mrd. USD mit einem Plus von 34 Prozent

Reuters
·
Feb 04

Regeneron reports FY Dupixent and Kevzara net product sales of USD 18.38 billion, up 26%

Reuters
·
Feb 04

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Regeneron (REGN)

TIPRANKS
·
Feb 03

Evercore ISI Keeps Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Feb 03

Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron (REGN)?

Simply Wall St.
·
Feb 03

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 03

Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says

MT Newswires Live
·
Feb 03

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Benzinga
·
Feb 03

Regeneron Pharma Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Feb 02

Regeneron Pharma Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 02

Oppenheimer Raises Price Target on Regeneron Pharmaceuticals to $865 From $750, Keeps Outperform Rating

MT Newswires Live
·
Feb 02

Regeneron Pharmaceuticals : Oppenheimer Raises Target Price to $865 From $750

THOMSON REUTERS
·
Feb 02